

Not All Unipolar Depressions Necessarily Chronic

BY BARBARA RUTLEDGE
Contributing Writer

MENDOZA, ARGENTINA — The use of antidepressants may not be effective for long-term treatment of unipolar depression, and may actually be harmful, Dr. Ulrik Malt reported at the 6th World Congress of Depressive Disorders.

"There are no good arguments for treating all unipolar depressions as a chronic disorder," said Dr. Malt, professor

of psychiatry at the University of Oslo. "There are no good reasons for long-term antidepressant treatment of all unipolar depressions."

In the absence of drug treatment, about 70% of patients go into remission within 6 months after a major depressive episode, and they may remain in remission for several years, with no or clinically insignificant symptoms of depression.

Support for the use of antidepressant drugs for treating unipolar depression

comes from clinical studies, but study results can be misleading

In many cases, according to Dr. Malt, the study population includes patients with other depressive disorders, rather than true unipolar depression, which he defined as a depressive episode without evidence of past hypomania or past symptoms of melancholia.

Published studies often include patients whose depression stems from bipolar spectrum disorders, which are neurobiologi-

cally distinct from unipolar depression.

Several studies have demonstrated that careful rediagnosis of patients given a diagnosis of major depressive disorder reveals a high incidence of patients with bipolar II disorder. These patients are more likely to respond to drug treatment than are patients with major depressive disorder.

Dr. Malt also questioned the data supporting long-term use of antidepressants for prevention of relapses, arguing that

In Kids, Response To Sertraline Varies With Age

Children with major depressive disorder aged 6-11 years have a significantly faster first response to both sertraline and a placebo, compared with adolescents aged 12-17 years, Dr. Craig L. Donnelly of Dartmouth-Hitchcock Medical Center in Lebanon, N.H., and his colleagues report.

The study, funded by Pfizer Inc., is the first known to examine the differences in time to first response and time to first persistent response in children and adolescents with major depressive disorder (MDD).

The investigators looked at 226 youths with MDD. The 10-week double-blind, placebo-controlled trial was followed by a 24-week open-label trial of sertraline (*J. Am. Acad. Child Adolesc. Psychiatry* 2006;45:1162-70). All of the patients who received sertraline started with a 25-mg/day dose for 3 days, followed by 50 mg/day through the end of 2 weeks. The dosage was then adjusted to a maximum of 200 mg/day based on the patient's clinical response and the occurrence of side effects.

The estimated median time to first response was 15 days for children and 22 days for adolescents who took sertraline, compared with 21 days for children and 23 days for adolescents who took a placebo. The time to first persistent response was significantly shorter in adolescents, but not in younger children, when compared with the placebo.

The estimated median time to first persistent response was 28 days for children and 32 days for adolescents who took sertraline, compared with 28 days for children and 32 days for adolescents who took a placebo. Patients in both age groups showed similar long-term improvements in MDD symptoms by the end of 34 weeks of treatment, and sertraline was generally well tolerated. Significantly more children than adolescents discontinued the study because of adverse events (15% vs. 4%).

Suicide-related events were reported in five patients in the sertraline group (three children, two adolescents) vs. two incidents in the placebo group (one adolescent attempted suicide twice). Those who reported suicide events were taking at least 100 mg of sertraline at the time of the events, but there was no link between the suicide events and any recent increase in the sertraline dose, the authors noted.

—Heidi Splete

FIRST
IN A NOVEL
CLASS OF
SLEEP
AGENTS

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use. Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.